Paid Clinical Trials in Alabama

Alabama has 1,295 paid clinical trials enrolling now across cities including Birmingham, Mobile and Huntsville. Search by condition, age, or phase to find compensated research studies accepting participants near you.

Both patients and healthy volunteers may qualify. Most studies offer compensation for time and travel.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: September 11, 2026.

Filter results

State

City

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

1,124 clinical trials

Get a weekly email when new trials open in Birmingham, AL.

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

for Focal Segmental Glomerulosclerosis

Sites in Huntsville, Alabaster +73 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 12+

Code: NCT07220083·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

for Peripheral Arterial Disease

Drug: Orforglipron

Sites in Birmingham +35 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07223593·Phase 3·Recruiting·Listed Nov 2025

Apply to this trial

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

for Carcinoma, Transitional Cell

Sites in Huntsville +63 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07218380·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

for Elevated Lp(a)

Drug: Muvalaplin

Sites in Birmingham +156 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07157774·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

for Diabetes Mellitus, Type 2

Drug: Empagliflozin

Sites in Fairhope, Anniston +202 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT07064473·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

for Major Depressive Disorder

Drug: Icalcaprant

Sites in Dothan +32 more locations

Sponsor: AbbVie

Sex: All·Age: 18 - 65

Code: NCT07276997·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder

for Alcohol Use Disorder

Drug: Brenipatide

Sites in Birmingham +29 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18 - 75

Code: NCT07219966·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

for Alzheimers Disease

Sites in Birmingham +67 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 50 - 90

Code: NCT07177352·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

for Cardiovascular Disease

Drug: Olpasiran

Sites in Birmingham, Mobile +192 more locations

Sponsor: Amgen

Sex: All·Age: 50 - 105

Code: NCT07136012·Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

for Obesity With Diabetes

Sites in Cullman +58 more locations

Sponsor: Kailera

Sex: All·Age: 18+

Code: NCT07284901·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

for Ovarian Neoplasms

Sites in Birmingham +86 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07213804·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

for Atherosclerotic Cardiovascular Disease

Sites in Mobile, Huntsville +135 more locations

Sponsor: Amgen

Sex: All·Age: 45 - 99

Code: NCT07037433·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

A Study of Dotinurad Versus Allopurinol in Participants With Gout

for Gout

Drug: Dotinurad

Sites in Birmingham, Foley +74 more locations

Sponsor: Crystalys Therapeutics

Sex: All·Age: 18 - 75

Code: NCT07089875·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

A Study of Dotinurad Versus Allopurinol in Tophaceous Gout

for Tophaceous Gout

Drug: Dotinurad

Sites in Birmingham, Foley +80 more locations

Sponsor: Crystalys Therapeutics

Sex: All·Age: 18 - 75

Code: NCT07089888·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia

for Dystonia

Sites in Birmingham +36 more locations

Sponsor: Vima Therapeutics

Sex: All·Age: 18 - 65

Code: NCT07304089·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

for Healthy

Sites in Birmingham, Mobile +116 more locations

Sponsor: Pfizer

Sex: All·Age: 1 Day - 49·Accepts healthy volunteers

Code: NCT07160244·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

for Metabolic Dysfunction Associated Steatohepatitis (MASH)

Drug: Survodutide

Sites in Birmingham +162 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06632444·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

for Metastatic Castration Sensitive Prostate Cancer (mCSPC)

Drug: Mevrometostat

Sites in Huntsville +123 more locations

Sponsor: Pfizer

Sex: Male·Age: 18+

Code: NCT07028853·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

for Triple Negative Breast Cancer

Sites in Birmingham, Huntsville +119 more locations

Sponsor: Gilead Sciences

Sex: All·Age: 18+

Code: NCT05633654·Phase 3·Recruiting·Listed Dec 2022

Apply to this trial

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for Breast Cancer

Sites in Daphne +171 more locations

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06492616·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

for Proteinuric Kidney Disease

Sites in Birmingham, Huntsville +137 more locations

Sponsor: Vertex Pharmaceuticals Incorporated

Sex: All·Age: 10 - 65

Code: NCT05312879·Phase 2, Phase 3·Recruiting·Listed Apr 2022

Apply to this trial

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

Drug: Amivantamab

Sites in Huntsville, Daphne +123 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06667076·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

for Endometrial Cancer

Sites in Mobile +67 more locations

Sponsor: Genmab

Sex: Female·Age: 18+

Code: NCT07166094·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

for End Stage Kidney Disease

Drug: Clazakizumab

Sites in Huntsville, Montgomery +146 more locations

Sponsor: CSL Behring

Sex: All·Age: 18+

Code: NCT05485961·Phase 2, Phase 3·Recruiting·Listed Aug 2022

Apply to this trial

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

for Plaque Psoriasis

Drug: Deucravacitinib

Sites in Birmingham +96 more locations

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 40+

Code: NCT07116967·Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

for Triple-Negative Breast Cancer

Sites in Mobile +82 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06393374·Phase 3·Recruiting·Listed May 2024

Apply to this trial

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

for Alzheimers Disease

Drug: Trontinemab

Sites in Birmingham +34 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 50 - 90

Code: NCT07169578·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

for Migraine

Drug: Ubrogepant

Sites in Huntsville, Saraland +85 more locations

Sponsor: AbbVie

Sex: All·Age: 6 - 17

Code: NCT05125302·Phase 3·Recruiting·Listed Nov 2021

Apply to this trial

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

Drug: LY3537982

Sites in Mobile, Huntsville +89 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06890598·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

for Early Breast Cancer

Drug: Ribociclib

Sites in Birmingham +77 more locations

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18 - 100

Code: NCT05827081·Phase 3·Recruiting·Listed Apr 2023

Apply to this trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

Drug: LY3537982

Sites in Huntsville +87 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06119581·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

for Breast Neoplasms

Sites in Daphne +33 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT07060807·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

for Atrial Fibrillation (AF)

Sites in Dothan, Fairhope +40 more locations

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT07175428·Phase 2·Recruiting·Listed Sep 2025

Apply to this trial

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Drug: Giredestrant

Sites in Daphne +11 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06065748·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

for Parkinson's Disease

Drug: Prasinezumab

Sites in Birmingham +52 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 50 - 85

Code: NCT07174310·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

for Lymphoma, Large B-Cell, Diffuse

Drug: Polatuzumab Vedotin

Sites in Mobile +70 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06890884·Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

for Neoplasms

Sites in Birmingham +76 more locations

Sponsor: Celgene

Sex: All·Age: All ages

Code: NCT03435796·Phase 2, Phase 3·Recruiting·Listed Feb 2018

Apply to this trial

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

for Metastatic Colorectal Cancer (CRC)

Drug: Bevacizumab

Sites in Mobile, Tuscaloosa +100 more locations

Sponsor: Summit Therapeutics

Sex: All·Age: 18+

Code: NCT07228832·Phase 3·Recruiting·Listed Nov 2025

Apply to this trial

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

for Chronic Spontaneous Urticaria (CSU)

Drug: Remibrutinib

Sites in Birmingham +128 more locations

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06868212·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

for Hidradenitis Suppurativa (HS)

Drug: Povorcitinib

Sites in Birmingham +25 more locations

Sponsor: Incyte Corporation

Sex: All·Age: 12 - 17

Code: NCT07213973·Phase 2·Recruiting·Listed Oct 2025

Apply to this trial